Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Open Access
- 4 October 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 392 (10155), 1311-1320
- https://doi.org/10.1016/s0140-6736(18)31652-0
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01 HL117861, R01 HL134811, K24 HL136852)
- NIH (R01-HL119828, R01-HL078610, R01 HL106579, R01 HL128550, R01 HL136098, P01 HL136275, R35 HL135737)
This publication has 38 references indexed in Scilit:
- Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)Journal of Lipid Research, 2013
- Genetic Associations with Valvular Calcification and Aortic StenosisThe New England Journal of Medicine, 2013
- Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)Journal of Lipid Research, 2012
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studiesInternational Journal of Epidemiology, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Lipoprotein Lp(a) and the risk for myocardial infarctionAtherosclerosis, 1981